Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults

NCT ID: NCT02610868

Last Updated: 2021-07-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE3
• Total Enrollment: 187 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-31
• Study Completion Date: 2017-06-30

Brief Summary

Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea.

Detailed Description

Multicenter, open-label, outpatient study of the safety and effectiveness of repeated doses of MYOBLOC over a 1-year duration in adult subjects with troublesome sialorrhea. The primary goal is to determine the long-term safety and tolerability of MYOBLOC (administered intraglandularly as single total dose of 3,500 Units) treatments every 13 weeks over a maximum possible duration of 1 year in adult subjects with troublesome sialorrhea. The secondary goal is to assess the magnitude of therapeutic response of MYOBLOC (administered intraglandularly as a single total dose of 3,500 Units) using effectiveness assessments performed at intervals after treatments every 13 weeks over a maximum possible duration of 1 year.

Conditions

Sialorrhea

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

MYOBLOC Injection

After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections over the course of 1 year.

Group Type: EXPERIMENTAL

MYOBLOC

Intervention Type: DRUG

After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47

Interventions

MYOBLOC

After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47

Intervention Type: DRUG

Other Intervention Names

rimabotulinumtoxinB; botulinum toxin type B

Eligibility Criteria

Inclusion Criteria

• Seeking treatment for troublesome sialorrhea for at least 3 months that is occurring secondary to any disorder or related to any cause, including, but not limited to, Parkinson's Disease (PD), adult cerebral palsy, amyotrophic lateral sclerosis (ALS), stroke, traumatic brain injury, oral cancer, and side effects of other medications.
• Able to read and provide written informed consent before enrollment into the study, or the subject's caregiver (Legally Authorized Representative) can provide written informed consent.
• Male or female, 18 to 85 years of age (inclusive).
• Minimum unstimulated salivary flow rate of 0.2 g/min at screening
• Minimum Investigator's Drooling Frequency and Severity Scale (DFSS) score of 4 at screening.
• Ability and availability to participate in the study for up to 1 year (ALS subjects: ability and availability to participate in the study for at least 6 months), based on overall health of the subject and disease prognosis

Exclusion Criteria

• A moderate to high risk of aspiration will exclude participation in this study. Subjects whose risk of aspiration are judged by the Investigator to be satisfactorily controlled by placement of PEG tube or G-tube for nutritional support are eligible to participate.
• Respiratory forced vital capacity (FVC) of <20% of predicted
• Prior botulinum toxin type A or B treatment in the salivary gland(s) identified for treatment in this study within 24 weeks before screening. Prior botulinum toxin type A or B treatment into other anatomical regions not selected for treatment in this study is not exclusionary, but must have occurred at least 12 weeks before screening
• Subjects should be excluded if, in the Investigator's opinion, the subject failed to respond to previous treatment with botulinum toxin. Subjects should not receive nor have any plans for receiving any botulinum toxin treatment, other than the study drug (MYOBLOC), during the entire course of the study (from the point the informed consent is signed until subject's participation is complete).
• Concomitant use, or exposure within 5 half-lives of screening, of aminoglycoside antibiotics, curare-like agents, or other agents that interfere with neuromuscular function
• Prior salivary gland surgery
• Current treatment or treatment at any time during the study with Coumadin® (warfarin) or similar anti-coagulant medications. Anti-platelet medications are not specifically exclusionary
• Evidence of any clinically significant neurologic disease
• Pregnancy or lactation
• Anticipated or scheduled surgery during the study period. A PEG tube/G tube may be placed for nutritional support at any time during the study and will not exclude the subject from continued study participation.
• Major surgery (requiring general anesthesia, except PEG tube/G tube placement ) within the previous 6 months before screening.
• Current infection at the sialorrhea treatment injection site(s)
• History of drug or alcohol abuse currently or within the previous 6 months
• Participation in another clinical drug, device, or biological agent study within 30 days of screening or while participating in this study

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Supernus Pharmaceuticals, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Najeebah Abdul-Musawir, MD,MBA

Role: STUDY_DIRECTOR

Supernus Pharmaceuticals, Inc.

Locations

Phoenix, Arizona, United States

Scottsdale, Arizona, United States

Scottsdale, Arizona, United States

Loma Linda, California, United States

Los Angeles, California, United States

Aurora, Colorado, United States

Atlantis, Florida, United States

Boca Raton, Florida, United States

Orlando, Florida, United States

Port Charlotte, Florida, United States

Atlanta, Georgia, United States

Kansas City, Kansas, United States

Overland Park, Kansas, United States

Elkridge, Maryland, United States

Farmington Hills, Michigan, United States

St Louis, Missouri, United States

Las Vegas, Nevada, United States

Edison, New Jersey, United States

Centerville, Ohio, United States

Tulsa, Oklahoma, United States

Greenville, South Carolina, United States

Cordova, Tennessee, United States

San Antonio, Texas, United States

Kirkland, Washington, United States

Spokane, Washington, United States

Tacoma, Washington, United States

Grodno, , Belarus

Dnipropetrovsk, , Ukraine

Ivano-Frankivsk, , Ukraine

Kharkiv, , Ukraine

Lviv, , Ukraine

Odesa, , Ukraine

Rivne, , Ukraine

Uzhhorod, , Ukraine

Zaporizhzhya, , Ukraine

Countries

United States; Belarus; Ukraine

References

Pahwa R, Molho E, Lew M, Dashtipour K, Gil RA, Revilla FJ, Clinch T, Qin P, Isaacson SH; OPen Label Trial of Intraglandular MYobloc injections for Sialorrhea Treatment (OPTIMYST) study group. Long-Term Safety and Efficacy of Repeated Cycles of RimabotulinumtoxinB in the Treatment of Chronic Sialorrhea: Results of the OPTIMYST Trial. Neurol Ther. 2025 Aug;14(4):1553-1567. doi: 10.1007/s40120-025-00777-z. Epub 2025 Jun 11.

Reference Type: DERIVED

PMID: 40498248 (View on PubMed)

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

SN-SIAL-351

Identifier Type: -

Identifier Source: org_study_id